Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

被引:0
作者
Princy Kumar
Edwin DeJesus
Gregory Huhn
Louis Sloan
Catherine Butkus Small
Howard Edelstein
Franco Felizarta
Ritche Hao
Lisa Ross
Britt Stancil
Keith Pappa
Belinda Ha
机构
[1] Georgetown University Hospital,ViiV Healthcare
[2] Orlando Immunology Center,undefined
[3] Ruth M Rothstein CORE Center,undefined
[4] Baylor University Medical Center,undefined
[5] New York Medical College,undefined
[6] Alameda County Medical Center,undefined
[7] Private Practice,undefined
[8] Chase Brexton Health Services,undefined
[9] Inc,undefined
[10] Research Triangle Park,undefined
[11] GlaxoSmithKline,undefined
[12] Research Triangle Park,undefined
来源
BMC Infectious Diseases | / 13卷
关键词
Abacavir; Cardiovascular biomarker; Efavirenz; Fosamprenavir; HIV; Lamivudine; Minority; Ritonavir; Underrepresented;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 293 条
[1]  
High KP(2012)HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group J Acquir Immune Defic Syndr 60 S1-S18
[2]  
Brennan-Ing M(2010)Does antiretroviral therapy increase or decrease the risk of cardiovascular disease? Curr HIV/AIDS Rep 7 92-98
[3]  
Clifford DB(2007)Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease J Clin Endocrinol Metab 92 2506-2512
[4]  
Cohen MH(2012)Sudden cardiac death in patients with human immunodeficiency virus infection J Am Coll Cardiol 59 1891-1896
[5]  
Currier J(2011)Cardiovascular implications from untreated human immunodeficiency virus infection European Heart J 32 945-951
[6]  
Deeks SG(2005)Race/ethnicity, income, major risk factors, and cardiovascular disease mortality Am J Public Health 95 1417-1423
[7]  
Deren S(2009)Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy HIV Med 10 79-87
[8]  
Effros RB(2011)Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir BMC Infect Dis 11 40-468
[9]  
Gebo K(2011)Change in high-sensitivity C-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals AIDS Res Hum Retroviruses 27 461-1556
[10]  
Gorozy JJ(2009)Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment AIDS 23 1547-1665